Spark Theraputics, a pharmaceutical company, has just made an exciting discovery! They've discovered a cure for a rare, genetic form of retinal dystrophy that leaves its victims blind.
Apparently, it can also cure any solvency in one’s bank account.— Christina Mellott (@catttaylor) January 4, 2018
Gene therapies pose a unique threat to pharmaceutical companies because they need only one treatment before the patient is "cured."
Maybe it is a reasonable price. Maybe it isn't. How about forcing medical suppliers to show their costs, and agreeing to a specific percentage markup as a profit? Certainly Pharma couldn't claim disclosure would hurt profits unless they meant windfall profits.— ttuforfree (@ttu5555) January 4, 2018
It's wildly expensive but, to be very frank, I think they've priced it what I'll call responsibly.
How many will be ready to accept the charge, blindly ? ☺☺☺— SHANKAR BARADHWAJ (@shankar6763) January 4, 2018
Our work is not done, but we believe that the offerings we are announcing today will help ensure that eligible U.S. patients have the coverage and financial support they need to gain access to both Luxtarna and the specialised medical care required to deliver the product at treatment centers.